Index of artpub/2022/277655/

Burger, J.A
Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features : integrated analysis of two phase 3 studies
2022
https://ddd.uab.cat/record/277655